UBS Reiterates Buy Rating on Celldex Therapeutics, Inc.
UBS maintains its buy rating on Celldex with a $45 price target.
Key Points
- UBS reiterated its buy rating for Celldex Therapeutics, Inc. (CLDX) with a $45 price target on June 10, 2026.
- Celldex shares are trading at $30.54 with a market cap of $2.45 billion and a 52-week range of $19.52 to $35.79.
- Wellington Management and Point72 Asset Management increased their positions in Celldex, while BlackRock and FMR reduced theirs.
UBS has reiterated its buy rating on Celldex Therapeutics, Inc. (NasdaqCM: CLDX), maintaining a price target of $45. This reaffirmation came on June 10, 2026, as Celldex shares traded at $30.54.
Other Institutional Activity in Celldex Therapeutics
Wellington Management Group increased its stake in Celldex by 480,868 shares, bringing its total to 8,560,476 shares valued at about $271.5 million. Point72 Asset Management notably grew its holdings by 1,471,582 shares, ending with 3,229,939 shares worth approximately $102.5 million. In contrast, BlackRock reduced its position by 81,930 shares, holding 5,369,885 shares valued at $170.3 million. FMR LLC also cut its stake by 1,158,421 shares, now holding 3,749,048 shares worth around $118.9 million.
Celldex Therapeutics, Inc. Stock Snapshot
Shares of Celldex Therapeutics, Inc. (NasdaqCM: CLDX) traded around $30.54. The company has a market capitalization of about $2.45 billion. The stock has a 52-week low of $19.52 and a high of $35.79, with a 50-day moving average of $31.95 and a 200-day moving average of $27.80. Celldex's forward P/E ratio is not meaningful as the company is not profitable, and it has a beta of 0.93, indicating lower volatility relative to the market.
Recent Earnings
Celldex reported revenue of $865,000 with a year-over-year decline of 97.8%. The company is currently not profitable, with a negative return on equity of -48.9%. The next earnings release is scheduled for May 7, 2026.
Insider Buying and Selling at Celldex Therapeutics, Inc.
Martin Samuel Bates, the SVP and CFO, bought 4,817 shares at an average price of $10.38 on January 2, 2026. On the same day, he also sold an equal number of shares. Ronald Pepin, Sr. VP & CBO, bought 19,333 shares at an average price of $5.47 on December 15, 2025, and later sold them.
Analysts Set New Price Targets
On June 10, 2026, UBS maintained its buy rating on Celldex with a $45 price target. Earlier, on May 13, 2026, Wells Fargo maintained a buy rating with a $54 target, and Barclays kept a buy rating with a $48 target on May 8, 2026. The consensus among 15 analysts is strong buy, with an average price target of $57.53.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company's pipeline includes Barzolvolimab, targeting chronic urticarias and other conditions, and CDX-622, aimed at inflammatory diseases. Led by CEO Anthony S. Marucci, the company employs 198 people.
Bottom Line
UBS's reaffirmation of its buy rating reflects continued optimism in Celldex's potential, despite its current lack of profitability. Investors closely monitor such analyst updates for insights into potential stock performance. It's important to remember that analyst ratings are forward-looking and do not guarantee future results.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.